As the University of Kansas Hospital prepares to proudly unveil their new proton beam machine, they should also be preparing to answer some tough questions about the cost and effectiveness of this therapy. More
When it comes to avoiding low-value care, doctors are just like the rest of us... More
What is the potential impact of trainees spending so little time on direct patients care? More
What are the potential consequences of widespread testing for preclinical Alzheimer's Disease? More
When you're facing a serious illness, navigating the health care system can be just as difficult as managing your physical health. In the latest edition of NPR's Life Kit series, Shannon Brownlee and other experts provide tips on how patients can maintain control over their health care in stressful situations. More
Although medication overload is particularly prevalent in older adults, younger people are not immune to harm from overprescribing, particularly when it comes to drugs for psychiatric conditions. Here is one person's story of harm from the psychiatric drug prescribing cascade. More
Can we trust drug companies to monitor and regulate the safety of their own products? More
Should patients be on the hook for ambulance rides for non-emergencies? It's not that simple, write Dr. Surafel Tsega and Dr. Harry Cho in JAMA. More
How health care institutions can address social determinants of health, beyond just screening and referral. More
Why decision aids aren't affecting patients' decisions about prostate cancer screening... More
It's not the hospitals you might expect... More
A recent CBS "Whistleblower" segment misses the big picture on midwives and maternity care. More
The latest commentary in the Lown Institute and American Family Physician's "Right Care" series features Dr. Andy Lazris and Dr. Alan Roth on the pros and cons of lung cancer screening. More
What happens when one low-value test leads to a "cascade" of expensive and harmful procedures? More
We know that consolidation among hospitals and insurance companies leads to higher prices. But what about consolidation in other areas of health care? More
Why measuring the outcomes of deprescribing is key for culture change, from family physician Maisha Draves at Kaiser Permanente. More
Is the FDA's accelerated approval program resulting in better cancer drugs? Two new studies provide insight... More
The approval of a new gene therapy to treat spinal muscular atrophy has created a hot debate in the health policy world about whether or not the drug's $2.1 million price tag is too expensive or a fair price. More
While we rush to fix the opioid crisis, are we ignoring another widespread drug problem? More
A group of pharmacists from Lifespan/Rhode Island Hospital answer our questions about how pharmacists can promote deprescribing. More